1. Home
  2. CELC vs HASI Comparison

CELC vs HASI Comparison

Compare CELC & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$53.29

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Hannon Armstrong Sustainable Infrastructure Capital Inc.

HASI

Hannon Armstrong Sustainable Infrastructure Capital Inc.

N/A

Current Price

$36.76

Market Cap

5.0B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
CELC
HASI
Founded
2011
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
5.0B
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
CELC
HASI
Price
$53.29
$36.76
Analyst Decision
Strong Buy
Buy
Analyst Count
13
15
Target Price
★ $150.85
$48.86
AVG Volume (30 Days)
920.9K
★ 974.5K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
★ 4.51%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 1.47
Revenue
N/A
★ $400,502,000.00
Revenue This Year
N/A
$394.02
Revenue Next Year
$1,921.71
$12.17
P/E Ratio
★ N/A
$25.62
Revenue Growth
N/A
★ 4.41
52 Week Low
$53.54
$31.07
52 Week High
$151.02
$44.13

Technical Indicators

Market Signals
Indicator
CELC
HASI
Relative Strength Index (RSI) 30.06 42.38
Support Level N/A $35.58
Resistance Level $72.76 $37.34
Average True Range (ATR) 4.24 1.18
MACD -1.03 -0.23
Stochastic Oscillator 0.16 0.00

Price Performance

Historical Comparison
CELC
HASI

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.

Share on Social Networks: